The MDMA Therapy Training Program was established in 2012 within the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) nonprofit founded in 1986. The training program is now operated by MAPS Public Benefit Corporation (MAPS PBC), a psychedelic pharmaceutical public benefit corporation wholly owned by MAPS. As of December 2021, the MDMA Therapy Training Program has trained nearly 2,000 clinicians in dozens of cohorts across the United States, Israel, Canada, Europe, and virtually. Trainees have come from around the world, representing more than a dozen countries and dozens of cultures.
Blended Format (Online & In-Person) Program Includes:
• One five and a half day in-person retreat with lead trainers (40 hours)
• Coursework, reading, and activities to complete before and after the retreat (60 hours)
Reports from previous participants in the MDMA Therapy Training Program:
• “This training has been a peak experience in my professional career!”
• “I arrived with the intention to be open, curious, embodied, and unattached to outcomes. And learn, I did- in the most enriching and inspiring ways.”
• “I didn’t quite know how much I longed for a diverse community of loving, supportive, and like-minded professionals until I found myself in the middle of one. To share a common mission and sense of purpose around healing is profoundly meaningful. For me, this was a coming home.”
MDMA Therapy Training Program Outline 100-hour Program
This program consists of live presentations, video case presentations, role play, scenario enactments, self-reflection activities, group and dyad activities, reading, writing, coursework, and creative projects.
Small groups, facilitated by MAPS Trainers, meet regularly throughout the program and provide a container for discussion, integration, process, and practice. Trainers and assistants are available to support trainees throughout the program.
The MDMA Therapy Training Program was established in 2012 within the Multidisciplinary Association for Psychedelic Studies (MAPS), a 501(c)(3) nonprofit founded in 1986. The training program is now operated by MAPS Public Benefit Corporation (MAPS PBC), a psychedelic pharmaceutical public benefit corporation wholly owned by MAPS. As of December 2021, the MDMA Therapy Training Program has trained nearly 2,000 clinicians in dozens of cohorts across the United States, Israel, Canada, Europe, and virtually. Trainees have come from around the world, representing more than a dozen countries and dozens of cultures.
Blended Format (Online & In-Person) Program Includes:
• One five and a half day in-person retreat with lead trainers (40 hours)
• Coursework, reading, and activities to complete before and after the retreat (60 hours)
Reports from previous participants in the MDMA Therapy Training Program:
• “This training has been a peak experience in my professional career!”
• “I arrived with the intention to be open, curious, embodied, and unattached to outcomes. And learn, I did- in the most enriching and inspiring ways.”
• “I didn’t quite know how much I longed for a diverse community of loving, supportive, and like-minded professionals until I found myself in the middle of one. To share a common mission and sense of purpose around healing is profoundly meaningful. For me, this was a coming home.”
MDMA Therapy Training Program Outline 100-hour Program
This program consists of live presentations, video case presentations, role play, scenario enactments, self-reflection activities, group and dyad activities, reading, writing, coursework, and creative projects.
Small groups, facilitated by MAPS Trainers, meet regularly throughout the program and provide a container for discussion, integration, process, and practice. Trainers and assistants are available to support trainees throughout the program.
MAPS Public Benefit Corporation (MAPS PBC) catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics prioritizing public benefit above profit. Founded in 2014, MAPS PBC is a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS) a 501(c)(3) nonprofit.
MAPS Public Benefit Corporation (MAPS PBC) catalyzes healing and well-being through psychedelic drug development, therapist training programs, and sales of prescription psychedelics prioritizing public benefit above profit. Founded in 2014, MAPS PBC is a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS) a 501(c)(3) nonprofit.
MAPS PBC is committed to collective liberation. We acknowledge the existence of historic and systemic oppression and recognizes that a truly liberated future can only exist if all people, including and especially those who have been impacted by these injustices, are included in its creation. Collective liberation recognizes that all of our struggles are intimately connected, and that within systems of oppression, everyone suffers.
The program aims to create a community of learning that facilitates knowledge sharing, networking, and cultivating the wisdom of each person and the group. All staff and trainees are expected to act in a respectful, inclusive, and non-discriminatory manner, and to take responsibility for their actions.
The MDMA Therapy Training Program is committed to addressing mental health disparities in psychedelic therapy as well as trauma treatment, especially those facing the most marginalized communities. In a commitment to address the current lack of diversity in psychedelic research, qualified clinicians from and serving communities of color, LGBTQIA+, people with disabilities, military populations, and other marginalized or underrepresented communities are strongly encouraged to apply.
